Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Numinus Wellness Inc T.NUMI

Alternate Symbol(s):  NUMIF

Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and... see more

TSX:NUMI - Post Discussion

Numinus Wellness Inc > California legalization is coming - Article from Sacramento
View:
Post by argon12 on Dec 31, 2020 12:09am

California legalization is coming - Article from Sacramento

Can psychedelic therapy reduce the mental health impacts of the coronavirus pandemic?


Pandemic strikes mean physical illness for many and trauma for all. The 2003 SARS outbreak led to terrifying increases in depression and post-traumatic stress disorder (PTSD) among caregivers, those quarantined and people affected in other ways. How can we prepare for the mental health impact of the coronavirus pandemic?

To address the inevitable spike of mental illnesses, we must hasten the approval of new evidence-based medications for depression and PTSD. These include the psychedelic compounds MDMA and psilocybin.

Twenty years of trials for psilocybin, and 10 years for MDMA, show that they outperform currently approved medications for depression and PTSD.

 

l.

Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities